Managing Toxicities from Immunotherapy

Created using ChatSlide

The ESMO guideline on immunotherapy toxicity management, published in October 2022, outlines a comprehensive approach to managing immune-related adverse events (irAEs). It emphasizes the importance of grading irAEs, excluding alternative causes before initiating immunosuppression, and reassessing treatment at 72 hours. The guideline covers various toxicities, including skin, endocrine, hepatic, gastrointestinal, pulmonary, neurological, cardiovascular, renal, ocular, and haematological...